Published in J Infect Dis on May 15, 2008
Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy. Proc Natl Acad Sci U S A (2009) 4.58
Redefining the viral reservoirs that prevent HIV-1 eradication. Immunity (2012) 2.56
Neurologic disease burden in treated HIV/AIDS predicts survival: a population-based study. Neurology (2010) 1.97
The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research. Antiviral Res (2009) 1.93
Molecular and pathologic insights from latent HIV-1 infection in the human brain. Neurology (2013) 1.88
Cliniconeuropathologic correlates of human immunodeficiency virus in the era of antiretroviral therapy. J Neurovirol (2009) 1.75
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Neuropsychological assessment of HIV-infected populations in international settings. Neuropsychol Rev (2009) 1.31
Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting. PLoS One (2011) 1.18
Raltegravir treatment intensification does not alter cerebrospinal fluid HIV-1 infection or immunoactivation in subjects on suppressive therapy. J Infect Dis (2011) 1.15
Cerebrospinal fluid (CSF) neuronal biomarkers across the spectrum of HIV infection: hierarchy of injury and detection. PLoS One (2014) 1.12
Improved neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group study a5199, the International Neurological Study. Clin Infect Dis (2012) 1.08
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One (2009) 1.08
Mononuclear phagocyte intercellular crosstalk facilitates transmission of cell-targeted nanoformulated antiretroviral drugs to human brain endothelial cells. Int J Nanomedicine (2012) 1.08
Positron emission tomography in patients suffering from HIV-1 infection. Eur J Nucl Med Mol Imaging (2009) 1.04
Neurotoxicity of human immunodeficiency virus-1: viral proteins and axonal transport. Neurotox Res (2011) 1.03
Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation. AIDS (2014) 0.98
CXCR3 activation by lentivirus infection suppresses neuronal autophagy: neuroprotective effects of antiretroviral therapy. FASEB J (2009) 0.97
A multinational study of neurological performance in antiretroviral therapy-naïve HIV-1-infected persons in diverse resource-constrained settings. J Neurovirol (2011) 0.96
HIV protease inhibitor exposure predicts cerebral small vessel disease. AIDS (2014) 0.92
The cannabinoid CB₂ receptor agonist AM1241 enhances neurogenesis in GFAP/Gp120 transgenic mice displaying deficits in neurogenesis. Br J Pharmacol (2014) 0.92
Should antiretroviral therapy for HIV infection be tailored for intracerebral penetration? Neth J Med (2009) 0.84
Incidence and predictors of adverse drug events in an African cohort of HIV-infected adults treated with efavirenz. Germs (2015) 0.83
Dimethyl fumarate modulation of immune and antioxidant responses: application to HIV therapy. Crit Rev Immunol (2013) 0.83
Molecular epigenetics, chromatin, and NeuroAIDS/HIV: translational implications. Bioinformation (2008) 0.82
ING116070: a study of the pharmacokinetics and antiviral activity of dolutegravir in cerebrospinal fluid in HIV-1-infected, antiretroviral therapy-naive subjects. Clin Infect Dis (2014) 0.82
Implementing neuronal plasticity in NeuroAIDS: the experience of brain-derived neurotrophic factor and other neurotrophic factors. J Neuroimmune Pharmacol (2013) 0.81
Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients. J Neuroinflammation (2010) 0.80
Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers. AIDS (2013) 0.79
Review of functional MRI in HIV: effects of aging and medication. J Neurovirol (2016) 0.78
Interactions between prostaglandins, leukotrienes and HIV-1: possible implications for the central nervous system. Retrovirology (2012) 0.77
Polyamines: Predictive Biomarker for HIV-Associated Neurocognitive Disorders. J AIDS Clin Res (2015) 0.75
Hearing Loss and Quality of Life (QOL) among Human Immunodeficiency Virus (HIV)-Infected and Uninfected Adults. J AIDS Clin Res (2016) 0.75
HIV-1-associated neurocognitive disorder: epidemiology, pathogenesis, diagnosis, and treatment. J Neurol (2017) 0.75
Updated research nosology for HIV-associated neurocognitive disorders. Neurology (2007) 16.18
The brain in AIDS: central nervous system HIV-1 infection and AIDS dementia complex. Science (1988) 6.51
Neurological complications of acquired immune deficiency syndrome: analysis of 50 patients. Ann Neurol (1983) 5.98
The AIDS dementia complex: II. Neuropathology. Ann Neurol (1986) 5.61
The AIDS dementia complex: I. Clinical features. Ann Neurol (1986) 5.22
Pharmacogenetics of efavirenz and central nervous system side effects: an Adult AIDS Clinical Trials Group study. AIDS (2004) 4.64
Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy. Annu Rev Immunol (2000) 4.46
Cerebrospinal fluid human immunodeficiency virus type 1 RNA levels are elevated in neurocognitively impaired individuals with acquired immunodeficiency syndrome. HIV Neurobehavioral Research Center Group. Ann Neurol (1997) 4.17
HIV and antiretroviral therapy in the brain: neuronal injury and repair. Nat Rev Neurosci (2007) 3.73
Early viral brain invasion in iatrogenic human immunodeficiency virus infection. Neurology (1992) 3.15
Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol (2004) 3.06
Relationship between human immunodeficiency virus-associated dementia and viral load in cerebrospinal fluid and brain. Ann Neurol (1997) 2.92
Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1. J Virol (2004) 2.91
HIV dementia: an evolving disease. J Neuroimmunol (2004) 2.88
The AIDS dementia complex. J Infect Dis (1988) 2.77
In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol (1997) 2.71
AIDS subacute encephalitis. Identification of HIV-infected cells. Am J Pathol (1987) 2.47
Progressive multifocal leukoencephalopathy revisited: Has the disease outgrown its name? Ann Neurol (2006) 2.39
Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure. J Infect Dis (2006) 2.36
Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals. Ann Intern Med (2005) 2.26
Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol (1996) 2.22
AIDS dementia complex and HIV-1 brain infection: clinical-virological correlations. Ann Neurol (1995) 2.14
Cortical and subcortical neurodegeneration is associated with HIV neurocognitive impairment. AIDS (2006) 2.13
Cortical dendritic pathology in human immunodeficiency virus encephalitis. Lab Invest (1992) 2.12
HIV in body fluids during primary HIV infection: implications for pathogenesis, treatment and public health. AIDS (2001) 2.08
Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status. Ann Neurol (1991) 2.08
Cerebrospinal fluid HIV infection and pleocytosis: relation to systemic infection and antiretroviral treatment. BMC Infect Dis (2005) 1.91
Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology (2000) 1.88
Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy. Neurology (2003) 1.83
Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA (2005) 1.80
CSF amyloid beta42 and tau levels correlate with AIDS dementia complex. Neurology (2005) 1.73
Clinical epidemiology and survival of progressive multifocal leukoencephalopathy in the era of highly active antiretroviral therapy: data from the Italian Registry Investigative Neuro AIDS (IRINA). J Neurovirol (2003) 1.70
Elevated cerebrospinal fluid levels of monocyte chemotactic protein-1 correlate with HIV-1 encephalitis and local viral replication. AIDS (1998) 1.70
The evolving face of human immunodeficiency virus-related progressive multifocal leukoencephalopathy: defining a consensus terminology. J Neurovirol (2003) 1.70
Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis (2005) 1.70
Biomarkers of HIV-1 CNS infection and injury. Neurology (2007) 1.69
Genetic composition of human immunodeficiency virus type 1 in cerebrospinal fluid and blood without treatment and during failing antiretroviral therapy. J Virol (2005) 1.68
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology (2006) 1.66
Increased human immunodeficiency virus type 1 (HIV-1) env compartmentalization in the presence of HIV-1-associated dementia. J Virol (2005) 1.65
HIV-1 Vpr causes neuronal apoptosis and in vivo neurodegeneration. J Neurosci (2007) 1.64
Mechanisms of neuronal injury and death in HIV-1 associated dementia. Curr HIV Res (2006) 1.61
Zidovudine treatment of the AIDS dementia complex: results of a placebo-controlled trial. AIDS Clinical Trials Group. Ann Neurol (1993) 1.61
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr (1999) 1.53
Human immunodeficiency virus encephalitis is the pathological correlate of dementia in acquired immunodeficiency syndrome. Ann Neurol (1994) 1.52
Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS (1999) 1.50
Mitochondrial alterations with mitochondrial DNA depletion in the nerves of AIDS patients with peripheral neuropathy induced by 2'3'-dideoxycytidine (ddC). Lab Invest (2001) 1.50
Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol (2005) 1.49
Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis (1998) 1.47
Antiretroviral use and other risks for HIV-associated neuropathies in an international cohort. Neurology (2006) 1.47
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
Immune reconstitution inflammatory syndrome in the CNS of HIV-infected patients. Neurology (2006) 1.45
Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatment. J Neurovirol (2005) 1.43
Neurological complications of HIV infection. Lancet (1996) 1.38
Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis (2007) 1.36
Distinct HIV-1 env sequences are associated with neurotropism and neurovirulence. Curr Top Microbiol Immunol (1995) 1.29
Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther (2005) 1.28
2',3'-dideoxycytidine (ddC) toxic neuropathy: a study of 52 patients. Neurology (1993) 1.28
Inflammatory reaction in progressive multifocal leukoencephalopathy: harmful or beneficial? J Neurovirol (2003) 1.27
A phase I/II trial of nimodipine for HIV-related neurologic complications. Neurology (1998) 1.27
Role of immune activation in HIV pathogenesis. Curr HIV/AIDS Rep (2007) 1.24
Clinical course and prognostic factors of progressive multifocal leukoencephalopathy in patients treated with highly active antiretroviral therapy. Clin Infect Dis (2003) 1.24
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
The effect of highly active antiretroviral therapy-induced immune reconstitution on development and outcome of progressive multifocal leukoencephalopathy: study of 43 cases with review of the literature. J Neurovirol (2003) 1.23
Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making. NeuroRx (2005) 1.23
CSF neurofilament protein (NFL) -- a marker of active HIV-related neurodegeneration. J Neurol (2007) 1.22
Compartmentalized human immunodeficiency virus type 1 present in cerebrospinal fluid is produced by short-lived cells. J Virol (2005) 1.22
Neuroimaging in human immunodeficiency virus infection. J Neuroimmunol (2004) 1.21
Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology (2007) 1.21
Skeletal muscle involvement in human immunodeficiency virus (HIV)-infected patients in the era of highly active antiretroviral therapy (HAART). Muscle Nerve (2005) 1.19
Influence of highly active antiretroviral therapy on persistence of HIV in the central nervous system. Curr Opin Neurol (2006) 1.18
Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis (1993) 1.17
Recent advances in HIV neuropathy. Curr Opin Neurol (2006) 1.17
Dynamics of monocyte chemoattractant protein type one (MCP-1) and HIV viral load in human cerebrospinal fluid and plasma. J Neuroimmunol (2005) 1.15
Molecular and cellular mechanisms of neuronal cell death in HIV dementia. Neurotox Res (2005) 1.15
Cerebrospinal fluid neopterin in human immunodeficiency virus type 1 infection. Ann Neurol (1990) 1.14
Complications associated with NRTI therapy: update on clinical features and possible pathogenic mechanisms. Antivir Ther (2004) 1.11
Human immunodeficiency virus type-1 protein Tat induces tumor necrosis factor-alpha-mediated neurotoxicity. Neurobiol Dis (2007) 1.09
Prolonged survival and partial recovery in AIDS-associated progressive multifocal leukoencephalopathy. Neurology (1988) 1.07
Efavirenz and chronic neuropsychiatric symptoms: a cross-sectional case control study. HIV Med (2006) 1.07
Measuring the "viral load" in cerebrospinal fluid in human immunodeficiency virus infection: window into brain infection? Ann Neurol (1997) 1.06
Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS (2001) 1.06
Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis (2007) 1.05
HIV-1 chemokine coreceptor utilization in paired cerebrospinal fluid and plasma samples: a survey of subjects with viremia. J Infect Dis (2005) 1.04
Continuing intrathecal immunoactivation despite two years of effective antiretroviral therapy against HIV-1 infection. AIDS (2002) 1.04
Evidence for independent development of resistance to HIV-1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS (2000) 1.04
Evaluation of the AIDS dementia complex in clinical trials. J Acquir Immune Defic Syndr (1990) 1.03
Dynamics of simian immunodeficiency virus populations in blood and cerebrospinal fluid over the full course of infection. J Infect Dis (2007) 1.02
Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J Clin Microbiol (1995) 1.01
Long-term virological effect of highly active antiretroviral therapy on cerebrospinal fluid and relationship with genotypic resistance. J Neurovirol (2004) 0.99
Antiretroviral drug treatment interruption in human immunodeficiency virus-infected adults: Clinical and pathogenetic implications for the central nervous system. J Neurovirol (2004) 0.99
Cerebrospinal fluid viral loads reach less than 2 copies/ml in HIV-1-infected patients with effective antiretroviral therapy. Antivir Ther (2006) 0.97
The role of monocytes and perivascular macrophages in HIV and SIV neuropathogenesis: information from non-human primate models. Neurotox Res (2005) 0.96
Neuropsychiatric complications of antiretroviral therapy. Drug Saf (2006) 0.94
Understanding pathogenesis and treatment of HIV dementia: a role for magnetic resonance? Trends Neurosci (2002) 0.94
HIV-1 reverse transcriptase sequence in plasma and cerebrospinal fluid of patients with AIDS dementia complex treated with Abacavir. AIDS (2001) 0.93
HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis (2010) 3.46
Central nervous system viral invasion and inflammation during acute HIV infection. J Infect Dis (2012) 2.37
Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther (2010) 1.99
Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy. J Infect Dis (2007) 1.92
Compartmentalization and clonal amplification of HIV-1 variants in the cerebrospinal fluid during primary infection. J Virol (2009) 1.70
Compartmentalized human immunodeficiency virus type 1 originates from long-lived cells in some subjects with HIV-1-associated dementia. PLoS Pathog (2009) 1.66
Persistent intrathecal immune activation in HIV-1-infected individuals on antiretroviral therapy. J Acquir Immune Defic Syndr (2008) 1.47
Antiretroviral treatment effect on immune activation reduces cerebrospinal fluid HIV-1 infection. J Acquir Immune Defic Syndr (2008) 1.46
HIV-1 replication in the central nervous system occurs in two distinct cell types. PLoS Pathog (2011) 1.45
Cerebrospinal fluid and neuroimaging biomarker abnormalities suggest early neurological injury in a subset of individuals during primary HIV infection. J Infect Dis (2013) 1.42
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurol (2009) 1.32
Change in brain magnetic resonance spectroscopy after treatment during acute HIV infection. PLoS One (2012) 1.25
Defining and evaluating HIV-related neurodegenerative disease and its treatment targets: a combinatorial approach to use of cerebrospinal fluid molecular biomarkers. J Neuroimmune Pharmacol (2006) 1.24
Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One (2009) 1.08
An example of genetically distinct HIV type 1 variants in cerebrospinal fluid and plasma during suppressive therapy. J Infect Dis (2013) 1.03
Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep (2015) 1.03
Approach to cerebrospinal fluid (CSF) biomarker discovery and evaluation in HIV infection. J Neuroimmune Pharmacol (2013) 0.98
Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation (2013) 0.95
Cerebral white matter integrity during primary HIV infection. AIDS (2015) 0.85
Enfuvirtide cerebrospinal fluid (CSF) pharmacokinetics and potential use in defining CSF HIV-1 origin. Antivir Ther (2008) 0.85
CNS reservoirs for HIV: implications for eradication. J Virus Erad (2015) 0.83
Peripheral neuropathy in primary HIV infection associates with systemic and central nervous system immune activation. J Acquir Immune Defic Syndr (2014) 0.80
Neuropsychological Impairment in Acute HIV and the Effect of Immediate Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 0.80
Treatment of HIV in the CNS: effects of antiretroviral therapy and the promise of non-antiretroviral therapeutics. Curr HIV/AIDS Rep (2014) 0.79
Single-copy assay quantification of HIV-1 RNA in paired cerebrospinal fluid and plasma samples from elite controllers. AIDS (2013) 0.79
Longitudinal characterization of depression and mood states beginning in primary HIV infection. AIDS Behav (2014) 0.78
Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. AIDS (2016) 0.77
High Number of Activated CD8+ T Cells Targeting HIV Antigens Are Present in Cerebrospinal Fluid in Acute HIV Infection. J Acquir Immune Defic Syndr (2017) 0.75